<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029612457709</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029612457709</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Uz</surname>
<given-names>Burak</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029612457709"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guven</surname>
<given-names>Gulay Sain</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029612457709">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Isik</surname>
<given-names>Ayse</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuyumcu</surname>
<given-names>Mehmet Emin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1076029612457709">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bektas</surname>
<given-names>Ozlen</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eliacik</surname>
<given-names>Eylem</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aksu</surname>
<given-names>Salih</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goker</surname>
<given-names>Hakan</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buyukasik</surname>
<given-names>Yahya</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sayinalp</surname>
<given-names>Nilgun</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haznedaroglu</surname>
<given-names>Ibrahim C.</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029612457709">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029612457709">
<label>1</label>Faculty of Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey</aff>
<aff id="aff2-1076029612457709">
<label>2</label>Faculty of Medicine, Department of Internal Medicine, Hacettepe University, Ankara, Turkey</aff>
<aff id="aff3-1076029612457709">
<label>3</label>Faculty of Medicine, Department of Geriatric Medicine, Hacettepe University, Ankara, Turkey</aff>
<author-notes>
<corresp id="corresp1-1076029612457709">Burak Uz, Faculty of Medicine, Division of Hematology, Hacettepe University, Ankara 06100, Turkey. Email: <email>burakuz78@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>338</fpage>
<lpage>340</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We have read with great interest the recent article published in the <italic>Clinical and Applied Thrombosis Hemostasis</italic> journal by Cakarer et al in which the authors suggested that topical Ankaferd blood stopper (ABS) application could be a safe and effective measurement for the bleedings of dental invasive procedures even under anticoagulant therapy without discontinuation of the antithrombotic medication. On average, 66.7% of the ABS-treated dental extraction sockets achieved hemostasis in less than 1 minute, while 80% of the nontreated sockets achieved hemostasis longer than 1 minute.<sup><xref ref-type="bibr" rid="bibr1-1076029612457709">1</xref></sup> Furthermore, there were no side effects associated with ABS use except a metallic taste in the mouth lasting for approximately 5 minutes. This investigation brilliantly indicates the efficacy of ABS for the clinical bleedings in the setting of acquired hemorrhagic diathesis.<sup><xref ref-type="bibr" rid="bibr1-1076029612457709">1</xref></sup></p>
<p>Hereafter, we would like to share our experience about topical ABS to control long-term sustained resistant site bleeding due to the bone marrow biopsy procedure in a bleeding-prone patient with secondary amyloidosis. Amyloid diseases can generally be associated with potentially life-threatening hemorrhages. Pathobiological factors contribute to abnormal bleeding tendency in amyloid diseases are heterogeneous depending on the type of amyloidosis and the pattern of organ involvement.<sup><xref ref-type="bibr" rid="bibr2-1076029612457709">2</xref></sup></p>
<p>A 31-year-old male Turkish patient with familial Mediterranean fever (FMF), secondary renal amyloidosis, and chronic kidney failure had presented with palor, lassitude, fatigue, thrombocytopenia, and deep anemia. His medications included <sc>l</sc>-thyroxine 1 × 0.1mg and colchium dispert 1-2 × 1 orally (po) daily. His familiy history was unremarkable and his parents were nonconsanguineous. In the physical examination, he had a significant pale appearance with numerous petechiaes in the upper body and both extremities. Moreover, massive splenomegaly (16 cm palpable below the left costal margin and extending to the inguinal and pelvic areas) with hypersplenism also complicated the clinical picture. Peripheral blood examination disclosed the hemoglobin level of 8.8 g/dL (13.6-17.2), white blood cell count of 9.0 × 10<sup>3</sup>/μL (4.3-10.3), with 6.4 × 10<sup>3</sup>/μL absolute count (70.6%) of neutrophils, and platelet count of 41 × 10<sup>3</sup>/μL (156-373). Peripheral blood smear showed 61% neutrophils, 38% lymphocytes, 1% eosinophils, poikilocytosis, hypochromia, anisocytosis, and decreased platelets. Nutritional and hemolytic anemia were ruled out. Baseline hemostatic parameters revealed the prolonged prothrombin time (international normalized ratio [INR]=1.4; N: 0.86-1.20) and increased <sc>d</sc>-dimer (5.88 μ/mL; N: 0-0.48) compatible with chronic disseminated intravascular coagulation (DIC). Meanwhile, coagulation factor (F) levels were as follows; factor VIII (FVIII): 57% (N: 53-170), FIX: 42% (N: 60-170), FXI: 59% (N: 70-150), FV: 17% (N: 70-120), FVII: 41% (N: 70-130), FX: 32% (N: 70-120), and antithrombin III: 67% (N: 80-120). Platelet function tests were abnormal with ADP (2 μmol/L), ADP (6 μmol/L), epinephrine (10 μmol/L), and collagen (1 ug/mL).</p>
<p>Bone marrow aspiration and biopsy have been performed at the spina iliaca posterior superior region of the iliac crest in order to assess amyloidosis. Bone marrow histopathology was normocellular and depicted increments in the megakaryocytes and plasma cells (7%-8%). Amyloid accumulation was detected around the blood vessels with crystal violet staining. After the invasive bone marrow procedure, significant persistent biopsy site bleeding represented a great clinical problem in the bleeding-prone patient. Despite the infusions of multiple platelet suspensions, fresh frozen plasma (FFP), and vitamin K administration, the local hemorrhage from the biopsy site did not stop. He received vitamin K 20 mg intravenously (iv) daily for 3 days, and 10 U of random platelet concentrates and 6 U of FFP. Also topical adrenalin was applied at the bleeding biopsy site. On the follow-up, the blood leakage continued for more than 10 days. Because of the long-term sustained persistent resistant biopsy site hemorrhage, topical ABS (Ankaferd Drug Inc, Istanbul, Turkey) of 4 mL was applied to the bleeding site (<xref ref-type="fig" rid="fig1-1076029612457709">Figure 1</xref>) with gentle compression. The local bleeding stopped within approximately 10 minutes (<xref ref-type="fig" rid="fig2-1076029612457709">Figure 2</xref>) and did not recur. Currently, clinical condition of the patient is favorable and no bleedings are noted from any areas of his body including biopsy site.</p>
<fig id="fig1-1076029612457709" position="float">
<label>Figure 1.</label>
<caption>
<p>Bleeding from the bone marrow biopsy site.</p>
</caption>
<graphic xlink:href="10.1177_1076029612457709-fig1.tif"/>
</fig>
<fig id="fig2-1076029612457709" position="float">
<label>Figure 2.</label>
<caption>
<p>The bleeding site was covered by the hemostatic network related with the Ankaferd blood stopper (ABS) application and hemorrhage was stopped.</p>
</caption>
<graphic xlink:href="10.1177_1076029612457709-fig2.tif"/>
</fig>
<p>The ABS is a novel topical hemostatic agent of plant origin. Several preclinical and clinical studies indicated that the hemostatic efficacy of ABS may be evident even in the presence of primary and/or secondary hemostatic abnormalities. Goker et al<sup><xref ref-type="bibr" rid="bibr3-1076029612457709">3</xref></sup> initially suggested that the addition of ABS to plasma in vitro did not affect the coagulation factors II, V, VII, VIII, IX, X, XI, and XIII. On the other hand, ABS had decreased plasma fibrinogen activity with the prolongation of the thrombin time in their study.<sup><xref ref-type="bibr" rid="bibr3-1076029612457709">3</xref></sup> The formation of an encapsulated protein network provided focal points for the aggregation of red blood cells following the ABS administration.<sup><xref ref-type="bibr" rid="bibr3-1076029612457709">3</xref>,<xref ref-type="bibr" rid="bibr4-1076029612457709">4</xref></sup> Thus, ABS seems to provide a protein-driven agglutination without significantly affecting the individual coagulation factors. In addition, the hemostatic effect of ABS may act as a topical biological response modifier by acting on protease-activated receptor I.<sup><xref ref-type="bibr" rid="bibr5-1076029612457709">5</xref></sup> Oral systemic Ankaferd administration was found to be safe based upon the in vivo rabbit experimental model.<sup><xref ref-type="bibr" rid="bibr6-1076029612457709">6</xref></sup> Recently, topical ABS was also found effective and safe for premature newborns with superficial cutaneous and mucosal bleedings.<sup><xref ref-type="bibr" rid="bibr7-1076029612457709">7</xref></sup> An in vivo study on rats disclosed that topically administrated ABS has a hemostatic effect alone or in the presence of warfarin effect.<sup><xref ref-type="bibr" rid="bibr8-1076029612457709">8</xref></sup> The efficacy of ABS in acetylsalicylic acid or enoxaparin-induced primary and secondary hemostatic abnormalities of a rat bleeding model was demonstrated.<sup><xref ref-type="bibr" rid="bibr9-1076029612457709">9</xref></sup></p>
<p>During clinicopathological complicated course of systemic light chain (AL) amyloidosis, acquired hemostatic abnormalities, including coagulation factor deficiencies, hyperfibrinolysis, and platelet dysfunction, can be regarded as the most important abnormalities affecting the hemostasis. In patients with other types of amyloidosis; acquired hemostatic defects are rare and amyloid deposition has also been reported to be the main cause of the abnormal bleeding manifestations.<sup><xref ref-type="bibr" rid="bibr2-1076029612457709">2</xref>,<xref ref-type="bibr" rid="bibr10-1076029612457709">10</xref></sup> Our patient had thrombocytopenia of hypersplenism, uremic platelet dysfunction, chronic DIC, and multiple coagulation factor deficiencies (FV, FVII, FIX, FX, FXI, and antithrombin III). Besides, vascular endothelial amyloid deposits with hyperfibrinolysis of amyloidosis also complicated the picture of bleeding diathesis. Therefore, he had both primary and secondary multiple serious defects of hemostasis. Likewise, amyloid deposition was documented in both kidneys and bone marrow of our patient. Amyloid angiopathy with increased fragility of blood vessels and impaired vasoconstriction may further promote bleeding in this complicated clinical setting.</p>
<p>Therapeutic options for bleeding caused by local amyloid deposition are usually restricted to supportive measures. Acquired hemostatic defects may be treated according to the causative mechanism.<sup><xref ref-type="bibr" rid="bibr2-1076029612457709">2</xref></sup> We add our voice to the Cakarer et al<sup><xref ref-type="bibr" rid="bibr1-1076029612457709">1</xref></sup> via reporting our present patient that topical ABS could be effectively used in patients with deficient primary and/or secondary hemostasis. Future randomized controlled trials are necessary to elucidate the clinical impact of topical ABS application for the management of the complicated bleedings of amyloidosis.<sup><xref ref-type="bibr" rid="bibr2-1076029612457709">2</xref>,<xref ref-type="bibr" rid="bibr10-1076029612457709">10</xref></sup></p>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029612457709"><label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029612457709"><label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029612457709">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cakarer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eyüpoglu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ozçamur Günes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gürkan Küseoglu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Koçak Berberoglu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Keskin</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Evaluation of the Hemostatic Effects of Ankaferd Blood Stopper During Dental Extractions in Patients on Antithrombotic Therapy [published online February 12, 2012]</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2012</year>.</citation>
</ref>
<ref id="bibr2-1076029612457709">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sucker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hetzel</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Grabensee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stockschlaeder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy</article-title>. <source>Am J Kidney Dis</source>. <year>2006</year>;<volume>47</volume>(<issue>6</issue>):<fpage>947</fpage>–<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr3-1076029612457709">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Ercetin</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Haemostatic actions of the folkloric medicinal plant extract, Ankaferd Blood Stopper</article-title>. <source>J Int Med Res</source>. <year>2008</year>;<volume>36</volume>(<issue>1</issue>):<fpage>163</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr4-1076029612457709">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haznedaroglu</surname>
<given-names>BZ</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>4</issue>):<fpage>446</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr5-1076029612457709">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karabiyik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Güleç</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Reversible protease-activated receptor 1 downregulation mediated by Ankaferd blood stopper inducible with lipopolysaccharides inside the human umbilical vein endothelial cells</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2011</year>;<volume>17</volume>(<issue>6</issue>):<fpage>E165</fpage>–<lpage>E170</lpage>.</citation>
</ref>
<ref id="bibr6-1076029612457709">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilgili</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Captug</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kosar</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Oral systemic administration of Ankaferd blood stopper has no short-term toxicity in an in vivo rabbit experimental model</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>5</issue>):<fpage>533</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr7-1076029612457709">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altunhan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Annagür</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tokgöz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Çaliskan</surname>
<given-names>Ü</given-names>
</name>
<name>
<surname>Örs</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Persistent nasal bleeding due to nasal CPAP application in 2 premature newborns successfully treated with topical “Ankaferd blood stopper”</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2011</year>;<volume>17</volume>(<issue>6</issue>):<fpage>E181</fpage>–<lpage>E182</lpage>.</citation>
</ref>
<ref id="bibr8-1076029612457709">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cipil</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kosar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2009</year>;<volume>15</volume>(<issue>3</issue>):<fpage>270</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr9-1076029612457709">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cipil</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The efficacy of Ancaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>2009</year>;<volume>20</volume>(<issue>3</issue>):<fpage>185</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr10-1076029612457709">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdem</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Celik</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Coagulation and fibrinolysis in amyloid and non-amyloid hemodialysis patients: assessment of local hemostatic kinetics within arteriovenous fistulas</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>1996</year>;<volume>2</volume>(<issue>4</issue>):<fpage>279</fpage>–<lpage>284</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>